Pharmaceuticals

Daniela Cavinatto takes the helm at Haleon Canada, bringing a playbook for transformation to a consumer health giant amid a market booming with new trends.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Inside the new Louisville hub where automation and an 'end-of-runway' strategy with UPS aim to redefine speed and precision in drug delivery.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

BWXT divests its medical arm to Nordic Capital, refocusing on its nuclear core while the private equity giant doubles down on the booming radiopharma market.

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

Amidst the fallout of its CEO's ouster, Anavex Life Sciences unveils a new board slate to fend off an activist investor's bid for total control.

Curium's landmark $8 billion acquisition of Lantheus is set to create a global powerhouse in nuclear medicine, reshaping patient care and the competitive landscape.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Lipocine's appointment of M&A veteran Michael Grissinger isn't just a new face on the board; it's a clear signal of a strategic pivot towards high-stakes partnerships.

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

Riding a wave of strong Q2 results, Supernus announces a merger of equals with Indivior, set to create a new, scaled player in CNS and addiction medicine.

Amid legal battles and policy shifts threatening the $100B 340B drug program, GPOs like HealthTrust are becoming critical navigators for hospital survival.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

Varda Space Industries adds a Pfizer legend to its board, signaling that the race to manufacture life-saving drugs in zero gravity is entering a new orbit.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.